Previous 10 | Next 10 |
SOUTH SAN FRANCISCO, Calif., March 29, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision oncology biopharmaceutical company, today announced that it intends to offer and sell shares of its common stock, warrants to purchase shares of its common...
Are These 3 Under $3 Meme Penny Stocks on Your Watchlist? Today, meme penny stocks and blue chips got a major bump. By EOD on March 28th, shares of AMC Entertainment Holdings Inc. ( NYSE: AMC ) and GameStop Corp. ( NYSE: GME ) had exploded by over 44% and 24% respectively. As we...
SOUTH SAN FRANCISCO, Calif., March 24, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision oncology biopharmaceutical company, today announced that the Company’s fourth quarter and full year 2021 financial results will be released on Thurs...
SOUTH SAN FRANCISCO, Calif., March 08, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision oncology biopharmaceutical company, today announced that it will present the first data from its preclinical synthetic lethality pipeline at the American A...
SOUTH SAN FRANCISCO, Calif., Feb. 16, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision oncology biopharmaceutical company, today announced that Susan Molineaux, Ph.D., the company’s founder, president and chief executive officer, will p...
AN2 Therapeutics Closed $80 Million Series B Financing to Advance Novel Nontuberculous Mycobacterial Lung Disease Program AN2 Board Expanded with the Appointment of Two New Directors PR Newswire MENLO PARK, Calif. , Jan. 7, 2022 /PRNewswire/ -- AN2 Therapeuti...
SOUTH SAN FRANCISCO, Calif., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision oncology biopharmaceutical company, today announced that Susan Molineaux, Ph.D., the company’s founder, president and chief executive officer, will p...
Intercontinental Exchange will add 138 securities to the ICE Biotechnology index and delete 26 as part of the annual reconstitution, effective prior to market open on December 20. Notable additions: Aurinia Pharmaceuticals (NASDAQ:AUPH), Anavex Life Sciences (NASDAQ:AVXL), Sesen Bio...
The Nasdaq Biotechnology Index will have a new look on December 20, before the market opens when 129 securities will be added and 21 securities will be deleted as part of the annual reconstitution. Notable additions to the index: Viatris (NASDAQ:VTRS), NovoCure (NASDAQ:NVCR), Anavex Life Scie...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Good morning, investor! We’re getting right into the thick of it today with a look at the biggest pre-market stock movers for Thursday! Source: ventdusud / Shutterstock.com Earnings reports, IPOs, acquisition...
News, Short Squeeze, Breakout and More Instantly...
Calithera Biosciences Inc. Company Name:
CALA Stock Symbol:
OTCMKTS Market:
Calithera Biosciences Inc. Website:
Williams Industrial Services Group Inc. (WLMSQ) is expected to report $-0.15 for Q3 2023 Cellcom Israel Limited (CELJF) is expected to report for quarter end 2023-09-30 Central Japan Railway Co ADR (CJPRY) is expected to report for Q2 2024 CW Petroleum Corp (CWPE) is expected to repor...
Strategic Environmental & Energy Resources Inc (SENR) is expected to report for Q1 2024 Biocept Inc. (BIOCQ) is expected to report for Q1 2024 Kalera Public Limited Company (KALRQ) is expected to report for quarter end 2023-09-30 Lanvin Group Holdings Limited (LANV) is expected to...
Murata Manufacturing Co. Ltd. ADR (MRAAY) is expected to report $0.27 for Q2 2024 Quotient Limited (QTNTQ) is expected to report for quarter end 2023-09-30 Evaxion Biotech A/S (EVAX) is expected to report for Q3 2023 American Virtual Cloud Technologies Inc. (AVCTQ) is expected to repo...